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doi:10.101Methotrexate Reduces the Incidence of Severe Acute
Graft-versus-Host Disease without Increasing the Risk
of Relapse after Reduced-Intensity Allogeneic Stem Cell
Transplantation from Unrelated Donors
Stephane Vigouroux,1 Reza Tabrizi,1 Cyril Melot,1 Joelle Coiffard,1 Xavier Lafarge,2
Gerald Marit,1 Krimo Bouabdallah,1 Arnaud Pigneux,1 Thibaut Leguay,1
Marie-Sarah Dilhuydy,1 Anna Schmitt,1 Jean-Michel Boiron,2 Noe¨l Milpied1Optimized prophylaxis against graft-versus-host disease (GVHD) after unrelated reduced-intensity alloge-
neic transplantation when preceded by a conditioning regimen utilizing antithymocyte globulin (ATG) is
poorly defined. To investigate the effects of methotrexate (MTX) in this treatment setting, we conducted
a retrospective analysis. Sixty-three patients were selected based on the administration of a total dose of
5 mg/kg of ATG in the conditioning regimen and then separated into either group M1 (n 5 39), which re-
ceived MTX or group M2 (n 5 24), which did not. All patients received cyclosporine. In the M2 and M1
groups, cumulative incidences (CI) of grade III-IV acute GVHD (aGVHD) were 43% and 10%, respectively
(P 5 .002). Multivariate analysis indicated that grade III-IV aGVHD was favored by both the absence of
MTX and the provision of a female donor for a male recipient. At 2 years, the M1 and M2 groups exhibited,
respectively: overall survival of 69% and 40% (P 5 .06), disease-free survival of 57% and 43% (P 5 .2), non-
relapse mortality of 20% and 44% (P5 .1), and incidence of relapse of 27% and 35% (P5 .6). These data sug-
gest that MTX reduces the incidence of severe aGVHD without increasing the risk of relapse but with an
accompanying trend toward improved survival after unrelated reduced-intensity transplantation with ATG
in the conditioning regimen.
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For more than 20 years, the use of a calcineurin in-
hibitor in combination with a short-course treatment
with methotrexate (MTX) has been the accepted
method of prophylaxis against acute graft-versus-host
disease (aGVHD) in patients treated with standard
myeloablative (MA) conditioning regimens. The semi-
nal study published in 1986 by the Seattle group
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6/j.bbmt.2010.06.013leukemia (AML) in first remission or chronic myeloge-
nous leukemia (CML) in chronic phase who received
bone marrow (BM) from an HLA-identical sibling.
The study reported that the cumulative incidence of
grade II-IV aGVHD under these circumstances was
significantly reduced in patients receiving cyclosporine
(CsA) in combinationwithMTXwhen compared to pa-
tients receiving CsA alone [1]. It is interesting to note
that the rate of survival after 1.5 yearswas also improved
in the patients receiving the addition of MTX [1].
Comparablyoptimizedprophylaxis against aGVHD
has yet to be as clearly defined for patients that have
been treated with reduced-intensity conditioning (RIC)
regimens, particularly when utilized in context with
antithymocyte globulin (ATG) and transplantation
sourced from an unrelated donor. What is currently
understood about aGVHD prophylaxis under these
conditions stems from evidence presented in recent
literature. It has been reported that the use of unre-
lated donors matched with recipients solely at the
allele level does not increase the risk of aGVHD
over that seen when utilizing related donors [2].93
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to correlate with a reduced risk of aGVHD after al-
logeneic stem cell transplantation (Allo-SCT) from
unrelated donors [3]. However, it has also been re-
ported that the peripheral blood stem cells that
are commonly transplanted after RIC regimens in-
creased the risk for the occurrence of aGVHD
when compared to the use of BM [4]. Taken to-
gether, these reports underline the difficulty in accu-
rately assessing the risk of aGVHD in patients after
treatment with unrelated RIC Allo-SCT concomi-
tant with ATG. As a consequence, the optimal
course of prophylaxis against aGVHD within this
specific treatment setting remains uncharacterized.
In light of the benefit to prophylactic efficiency
garnered from the inclusion of both a calcineurin in-
hibitor and MTX in MA treatments, questions arise
about the potential effectiveness of these agents in
a setting wherein RIC is the conditioning regimen.
As a calcineurin inhibitor has always been used stan-
dardly in RIC treatment, the true debate centers on
the usefulness of the addition of a short-course treat-
ment of MTX. Therefore, in an effort to explore the
prophylactic effects of MTX on aGVHD prophylaxis
in patients after treatment with unrelated RIC Allo-
SCT in conjunction with ATG, we conducted a retro-
spective analysis of Allo-SCT procedures performed at
our center in Bordeaux between 2005 and 2009.PATIENTS AND METHODS
Selection of Patients
The parameters of the selection criteria for inclu-
sion in this study were set to select a population of
patients that included adults over the age of 18 years
diagnosed with hematologic malignancies, treated
with an RIC regimen that included rabbit ATG (Thy-
moglobuline) at a total dose of 5 mg/kg followed by
an Allo-SCT from an unrelated donor and whose
treatments were performed between January 2005
and October 2009 at our center in Bordeaux. In the
interest of standardizing the parameters of this study,
patients who received a secondary dose of ATG or
who did not receive ATG at all were excluded from
this study as were patients who received mycopheno-
late mofetil (MMF).
During the study period, patients at our center
eligible for an unrelated allogeneic transplant were
first offered the choice of participation in a clinical trial
evaluating the toxicity and the efficacy of a RIC
regimen that included fludarabine (Flu), treosulfan,
and ATG if they met the inclusion criteria: 18 to 65
years, matched unrelated donor, multiple myeloma,
or chronic lymphocytic leukemia (CLL), or myelodys-
plastic syndrome, or AML or acute lymphoblastic
leukemia (ALL) with abnormal karyotype in firstremission, or AML or ALL beyond the first remission.
In this trial, CsAwas the standard prescribed treatment
used for the prevention of GVHD, whereas MTX was
added only in cases withminor ABOmismatch or if the
donor was female.
Patients under the age of 50 years who elected not
to participate in the treosulfan-inclusive trial as well as
those patients found to be ineligible because of lack of
available matching donor or contraindicated diagnosis
as listed before, were either treated with MA regimen
and thus removed from contention for analysis in the
present investigation or, if found to be unfit for such
intensive treatment, offered an RIC regimen with
Flu, busulfan (Bu), and ATG. Patients 50 years of
age or older systematically received this same Bu-
inclusive RIC regimen.
Sixty-three patients were identified by this criteria
and included in the analysis reported in the present
study. Information concerning donors, recipients,
graft harvesting, and follow-up procedures were
collected using prospectively designed forms. Data
from the Treosulfan trial is currently unpublished
but used by permission of study authors.
Patients’ Transplant-Related Characteristics
All patients began receiving CsA the day before
graft infusion and were maintained between a target
blood level range of 200 and 400 ng/mL for 3 months,
before being tapered off over a 2- to 3-month period
once found to be free of any incidence of GVHD.
Each patient was treated with either 1 of 2 condition-
ing regimens: Flu1Bu1ATGor Flu1Treosulfan1
ATG. In both instances, Flu was administered at 30
mg/m2/day intravenously (i.v.) for 5 consecutive
days, whereas Rabbit ATG (Thymoglobuline) was
administered i.v. at 2.5 mg/kg/day for 2 consecutive
days at day 22 and day 21, where day 0 was the day
of graft infusion. Bu was administered at 1 mg/kg
orally (p.o.) (or 0.8 mg/kg i.v.)  4/day for 2 consecu-
tive days. Treosulfan was administered at 12 g/m2/day
i.v. for 3 consecutive days. All patients received pro-
phylactic antiinfectious agents according to the guide-
lines published in 2001 by the Center for Disease
Control and Prevention, the Infectious Diseases Soci-
ety of America, and the American Society for Blood
and Marrow Transplantation [5]. aGVHD and
chronic GVHD were graded according to the Seattle
criteria [6,7].
Statistical Analysis
The distribution of variables between groups was
calculated using either the Fisher’s exact test or the
chi-square test, as appropriate. Overall survival (OS)
was measured from the date of transplantation to
either the date of death from any cause or last
follow-up. Disease-free survival (DFS) was measured
Biol Blood Marrow Transplant 17:93-100, 2011 95Methotrexate for Prevention of Graft-versus-Host Diseasefrom the date of transplantation to the date of relapse,
progression, death from any cause or last follow-up.
Nonrelapse mortality (NRM) was defined as all causes
of death other than disease relapse or progression oc-
curring at any time after transplantation. Survival esti-
mates were determined either by the Kaplan andMeier
method with subsequent comparison to the log-rank
test (univariate analysis) or by the Cox proportional
hazards regression model (multivariate analysis).
Probabilities of GVHD, relapse, and NRM were cal-
culated using cumulative incidence (CI) functions to
allow for competing risks such as death without relapse
when considering relapse and relapse and death when
considering GVHD. Variables included in the univar-
iate analyses were MTX (with versus without), age
($ versus \50 years), conditioning regimen (with
versus without treosulfan), HLA mismatches (0 versus
1), ABO mismatches (0 versus 1), sex mismatches
(specifically female donor for male recipient versus
other combinations), number of CD34 positive cells
(\versus $8  106), graft source (peripheral blood
versus BM) and status of disease (CR1 versus others).
Variables that generated P values\.1 in the univariate
analyses (MTX, conditioning regimen, sex mis-
matches) were entered in a multiple Cox model and
sequentially removed from the model if they were
not significantly associated with the outcome at the
.05 level.RESULTS
Characteristics of Patients
The patients selected for inclusion in this study
were divided into 2 analytical groups defined by the
use of MTX for the prevention of GVHD. The group
designated M1 (n 5 39) received MTX at 15 mg/m2
i.v. at day 11 and 10 mg/m2 i.v. at both day 13 and
day 16. Folinic acid was administered at a dose of 50
mg i.v. at 12, 24, and 36 hours after each dose of
MTX. Group M2 (n 5 24) did not receive MTX for
1 of the following reasons: inclusion in the treosulfan
trial (n5 14), severe hepatitis contibutable to the con-
ditioning regimen precluding the administration of
MTX (n5 1), or physician’s decision without any spe-
cific reason documented but likely because of the lack
of evidence supporting the systematic use of MTX
after RIC Allo-SCTwhen ATG is included in the con-
ditioning regimen (n 5 9). The patients’ characteris-
tics for both groups M1 and M2 are summarized in
Table 1. No significant difference was found regarding
disease, status of disease at transplant, HLA mis-
matches, ABO mismatches, female donor for male
recipient, source of stem cells, number of CD341 cells,
or year of transplant. However, statistical differences
were identified when considering patient age and
particular type of conditioning regimen. Patients inthe M2 group were significantly younger, with a me-
dian age of 49 years compared to 57 years in the M1
group. Moreover, more patients in the M2 group
received treosulfan in the conditioning regimen than
did those in theM1 group (14 in theM2 group versus
1 in the M1 group; P\.001). The imbalance in age
was closely related to the imbalance in conditioning
regimen because the therapeutic strategy at our treat-
ment center during the period of this study was to first
offer patients the choice of participation in the treosul-
fan trial when a matched donor was available. The
treosulfan trial included patients from 18 to 65 years
and, as a consequence, all patients \50 years with
a matched donor were preferentially transplanted in
the treosulfan trial even if they were fit enough for
an MA regimen. The prescribed parameters of the
treosulfan trial did not include the systematic use of
MTX, thus causing the M2 group to skew toward
a younger patient population.
GVHD
As a whole, the study participants exhibited CIs for
grade II-IV and grade III-IV aGVHD of 40% (95%
CI, 34%-46%) and 23% (95%CI, 18%-28%), respec-
tively. As shown in Figure 1A, the CI of grade II-IV
aGVHD for groups M2 and M1 were 52% and
32%, respectively (P5 0.07), whereas the correspond-
ingCI of grade III-IV aGVHD, as shown in Figure 1B,
were 43% and 10%, respectively (P 5 .002). Univari-
ate analyses indicated that the incidence of grade
III-IV aGVHD was also favored by the use of condi-
tioning regimen that included treosulfan (P 5 .049)
and the provision of a female donor for amale recipient
(P 5 .01). Multivariate analysis indicated that grade
III-IV aGVHD was favored by the absence of MTX
(P 5 .03; hazard ratio [HR], 4.48; 95% CI,
1.14-17.57), as well as by the provision of a female
donor for a male recipient (P 5 .04; HR, 3; 95% CI,
1.03-8.78).
The CI of extensive cGVHD was 27% (95% CI,
19%-35%) for the group overall and 20% or 30%
(P 5 .4) in the M2 and M1 groups, respectively.
Survival and Relapse
Considered as a whole andwith amedian follow-up
of 25 months (range: 3-59 months) the participants
experienced 2-year OS, DFS, NRM, and incidences
of relapse of 59% (95% CI, 52%-66%), 51% (95%
CI, 44%-58%), 28% (95% CI, 21%-35%), and 30%
(95%CI, 23%-37%), respectively (Figure 2). As shown
in Figure 3, when considered separately in theM1 and
M2 groups, respectively, the 2-yearOSswere 69%and
40% (P 5 .06); the 2-year DFSs were 57% and 43%
(P 5 .2); the 2-year NRMs were 20% and 44%
(P 5 .1); and the 2-year incidences of relapse were
27% and 35% (P 5 .6).
Table 1. Characteristics of Patients Included in Study Separated into Groups Treated with (M+) or without (M2) Methotrexate
M+
n 5 39
M2
n 5 24
n % n % P
Age (years)
Median 57 49
Range 17-65 16-66
<50 years 7 17.9 13 54.2 .003
$50 years 32 82.1 11 45.8
Disease
Acute myelogenous leukemia 17 43.6 11 45.8 NS
Acute lymphoblastic leukemia 4 10.3 1 4.2 NS
Lymphoma 10 25.6 3 12.5 NS
Myelodysplastic Syndrome 4 10.3 3 12.5 NS
Myeloma 3 7.7 4 16.7 NS
Myeloproliferative disease 1 2.6 1 4.2 NS
Chronic lymphocytic leukemia 0 1 4.2 NS
Status of disease at transplant
CR1 15 38.5 5 20.8 NS
$CR2 12 30.7 5 20.8 NS
$PR2 5 12.9 5 20.8 NS
Refractory 4 10.3 5 20.8 NS
Untreated 3 7.7 4 16.7 NS
Conditioning regimen <.001
Fludarabine-Busulfan-ATG 38 97.4 10 41.7
Fludarabine-Treosulfan-ATG 1 2.6 14 58.3
HLA mismatches
None* 24 61.5 20 83.3 NS
HLA-C† 9 23.1 3 12.5 NS
HLA-A or -B or -DR or -DQ‡ 6 2.6 1 4.2 NS
ABO mismatches
None 16 41 10 41.7 NS
Major 15 38.5 6 25 NS
Minor 7 17.9 6 25 NS
Bidirectional 1 2.6 2 8.3 NS
Female donor, male recipient NS
No 32 82.1 18 75
Yes 7 17.9 6 25
Graft source NS
Peripheral blood 36 92.3 22 91.7
Bone marrow 3 7.7 2 8.3
Number of CD34+ cells (106/kg)
Median 8.2 8 NS
Range 1.9-18.6 1.5-18.3
Year of transplant
2005 7 17.9 5 20.8 NS
2006 11 28.2 6 25 NS
2007 10 25.6 3 12.5 NS
2008 3 7.7 2 8.3 NS
2009 8 20.5 8 33.3 NS
NS indicates not significant; CR, complete response; PR, partial response; ATG, antithymocyte globulin.
*At the allele level.
†In the M+ group: 7 single antigen mismatches and 2 single allele mismatches; in the M2 group: 3 single antigen mismatches.
‡In the M+ group: 1 single antigen mismatch and 5 single allele mismatches; in the M2 group: 1 single antigen mismatch.
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M2 group died. The causes of death are summarized
in Table 2, with the lead cause being aGVHD in the
M2 group and progression or relapse of the disease
in the M1 group.DISCUSSION
Although the focus of the present study is the
investigation of the prophylactic potential of MTX
to reduce the incidence of aGVHD in allo-RIC, the
data utilized was collected under circumstances wherepatients received treosulfan in their conditioning reg-
imens (n 5 15) in the setting of a clinical trial that
chose CsA as the principal treatment for the preven-
tion of aGVHD, using MTX only in cases limited to
mismatches in ABO and donor-patient sex. These
treosulfan1 patients therefore represented the major-
ity of subjects in the M2 group and were found to ex-
perience a greater incidence of grade III-IV aGVHD
when compared to the patients in the M1, largely
treosulfan2 group. The subsequent question of the
likelihood of a putative confounding role for treosulfan
in the occurrence of severe aGVHD was evaluated by
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Figure 1. Acute GVHD grade II-IV (A) and grade III-IV (B) in patients treated with (M1, n 5 39) or without (M2, n 5 24) MTX.
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cluded treosulfan as a factor favoring the incidence of
grade III-IV aGVHD. In addition, a survey of the rel-
evant literature finds no evidence to support a bias to-
ward aGVHD when using treosulfan in this setting.
Indeed, when the RIC regimen combining Flu and
treosulfan was pioneered in Germany by Casper
et al. [8] in 2004, the rationale for using treosulfan in
this setting was cited as being specifically reliant on
its significant antitumor activity combined with its
limited nonhematologic toxicity. Additionally, subse-
quent studies, combining RIC-Allo SCT with treosul-
fan, report that the rates of incidence for grade II-IV
aGVHD and grade III-IV aGVHD vary between
23% and 33% and 12% and 30%, respectively [8-
10]. Taken together, this information does not
support the existence of an increased risk of aGVHD
because of the use of treosulfan in the conditioning
regimen over that seen in an RIC regimen without
treosulfan. Thus, it is highly unlikely that treosulfan
plays a confounding role in the present study.
A similar concern over potential factor-driven bias
arises when note is taken of a seeming discrepancy in
age distribution between the M2 and M1 groups,
wherein the older M1 population exhibited a reduced0 10 20 30 40 50 60
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Figure 2. OS, DFS, treatment-related mortality, and inincidence of aGVHD. As noted in the Results section
under Characteristics of Patients, the difference in age
between the 2 groups was a circumstantial conse-
quence of the ongoing treosulfan clinical trial being
conducted during the time frame of our study. When
subjected to statistical analysis, however, this differ-
ence in overall age between the 2 groups was excluded
from consideration as a factor that could have an im-
pact on the incidence of severe GVHD. Also, the ad-
vanced age of patients in the M1 group may be
further excluded as a major bias for the reduced inci-
dence of aGVHD that was observed in light of the
knowledge that advanced age itself is a well-known
risk factor for aGVHD [11] and, therefore, could not
possibly favor a decrease in the incidence of GVHD.
The use of MTX as a prophylactic agent against
GVHD when administered as a short-course treat-
ment is a subject that has been the focus of several re-
cent investigative protocols. A review of the results of 8
studies from the relevant literature is summarized in
Table 3 [1,12-20]. The particulars of these studies
vary in areas such as conditioning regimens, where 6
of the 8 studies were MA in nature, and in type of
disease investigated, where 2 of the 8 studies focused
on nonmalignant diseases, namely, severe aplastic0 10 20 30 40 50 60
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Figure 3. OS, DFS, treatment-related mortality, and incidence of relapse in patients either treated with MTX (M1, n 5 39) or not (M2, n 5 24).
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in Iravani et al.’s study [20]. Despite these disparate
conditions, most of these studies reported decreased
incidences of aGVHD with the addition of a short
course of MTX. Of particular note, the 3 randomized
studies included in this overview that focused on
hematologic malignancies consistently reported de-
creased incidences of aGVHD with the use of MTX
[1,14,16]. Interestingly, neither the incidence of
cGVHD nor that of relapse was influenced by the
presence of MTX in any of the studies reviewed.
Despite some differences in our study design,
namely, the use of unrelated donors and the
inclusion of ATG in conditioning regimens, we
report highly comparable results in regard to the
incidences of aGVHD, cGVHD, and relapse. In
regard to survival, the decreased incidence of
aGVHD reported in the pertinent literature did not
generally translate into improved rates of survival
(see Table 3). The only exception was the study of
nonmalignant severe aplastic anemia by Locatelli
et al. [15] that reported improved survival rates in the
presence of a combination of CsA and MTX when
compared to CsA alone (94% versus 78%; P 5 .05).
They also reported in parallel a reduced incidence of
NRM (6% vs 16%, P 5 .07). However, in studies fo-
cusing on patients with malignant diseases, the impactTable 2. Causes of Death in Patients by Group: Treated with
(M+) or without (M2) Methotrexate
M+
n 5 13
M2
n 5 12
Acute GVHD 1 5
Disease 5 3
MOF 1 1
ARDS 2 0
Hemorrhage 0 1
Septic shock 2 1
EBV-PTLD 0 1
Bronchiolitis obliterans 1 0
Encephalitis 1 0
MOF indicates multiorgan failure; ARDS, acute respiratory distress
syndrome; PTLD, posttransplant lymphoproliferative disease; EBV,
Epstein-Barr virus; GVHD, graft-versus-host disease.on survival is less clear. Storb et al. [12,13] reported
a trend toward improved rate of survival in patients
with CML, whereas patients with AML exhibited no
difference in survival rate regardless of treatment
with MTX. In the other studies investigating
malignant disease, the addition of MTX did not
significantly increase rates of survival. In the present
study, we report comparable results with regard to
trends toward improved survival rates (69% versus
40%, P 5 .06) and a reduced NRM (20% versus
44%, P 5 .1) in patients treated with both CsA and
MTX.
Reports in recent literature support the idea of
a cooperative role for additional prophylactic agents
used in combination with CsA for the prevention of
GVHD. Chief among these agents is MMF. A small
randomized trial showed that the use of CsA and
MMF was associated with a reduced severity of
mucositis, faster hematopoietic engraftment, similar
incidences of aGVHD or cGVHD, and comparable
survival compared to the combination of CsA and
MTX [21]. Unfortunately, the small sample size in
the study relegates its findings to a mostly prospective
nature. Nevertheless, subsequent studies have con-
firmed that the combination of CsA with MMF was
a valid and safe option for the prevention of GVHD af-
ter eitherMA [22] or nonmyeloablative [23] condition-
ing regimens, thereby lending credence to therapeutic
approaches that include additional prophylactic agents
in a noncompetitive role when used in combination
with CsA.
In conclusion, it must be acknowledged that the
retrospective nature and modest size of our study pre-
clude the declaration of any firm conclusions. It does,
however, present information that suggests this matter
warrants further investigation in the form of a larger
prospective study. Nevertheless, despite concerns
over the breadth of this study, our data does suggest
that treatment with a short course of MTX reduces
the incidence of severe aGVHD without increasing
the risk of relapse after unrelated RIC transplantation
when 5 mg/kg of ATG is included in the conditioning
Table 3. Review of Studies Investigating Prophylaxis of Methotrexate Against Graft-versus-Host Disease
Comparison Disease CR D ATG
aGVHD
II-IV TRM CGVHD Relapse Survival
Storb et al.*[1,12,13] CsA versus
CsA/MTX
AML-CR1
CML-CP
MA Sib No 54% versus
33%
P 5 .01
46% versus
26%
P 5 .07
24% versus
26%
P 5 .79
AML:
19% versus 29%
P 5 .6
CML:
7% versus 4%
P 5 .5
AML:
38% versus 41%
P 5 .6
CML:
45% versus 69%
P 5 .08
Chao et al.*[14] CsA/PDN versus
CsA/PDN/MTX
AL-CR1
CML-CP
LL-CR1
MA Sib No 23% versus
9%
P 5 .02
NA 60% versus
57%
P 5 ns
P 5 ns 59% versus
46%
P 5 ns
Locatelli et al.*[15] CsA versus
CsA/MTX
SAA RIC Sib No 38% versus
30%
P 5 ns
19% versus
6%
P 5 .09
30% versus
44%
P 5 ns
NA 78% versus
94%
P 5 .05
Zikos et al.*[16] CsA versus
CsA/MTX
AML MA Sib No 61% versus
34%
P 5 .02
17% versus
11%
P 5 .6
P 5 ns 32% versus
14%
P 5 .1
67% versus
74%
P 5 .1
Ho et al.[17] Sir/Tac versus
Sir/Tac/MTX
Hematologic
Malignancies
RIC Sib No 17% versus
11%
P 5 .46
P 5 ns P 5 ns P 5 ns P 5 ns
Uberti et al.[18] Tac versus
Tac/MTX
Hematologic
Malignancies
MA Sib No 35% versus
23%
P 5 .1
NA 53% versus
50%
P 5 .5
36% versus
7%
P 5 .07
Good risk
P 5 .07
Poor risk
P 5 .1
Aschan et al.[19] CsA versus
CsA/MTX
AL MA Sib No 47% versus
8%
P <.01
NA 40% versus
25%
P 5 ns
NA 53% versus
56%
P 5 ns
Iravani et al.[20] CsA versus
CsA/MTX
Thalassemia MA Sib No
21
78% versus
52%
P 5 .003
18% versus
14%
P 5 .6
27% versus
36%
P 5 .2
NA 77% versus
85%
P 5 .6
CR indicates conditioning regimen; D, donor; ATG, antithymocyte globulin; aGVHD, acute graft-versus-host disease; TRM, treatment-related mortality;
cGVHD: chronic graft-versus-host disease; CsA, cyclosporine A; MTX, short-course of methotrexate; AML, acute myelogenous leukemia; CR1, first
complete response; CML, chronic myelogenous leukemia; CP, chronic phase; Sib, sibling; MA, myeloablative; PDN, prednisone; AL, acute leukemia;
LL, lymphoblastic lymphoma; NA, not available; SAA, severe aplastic anemia; RIC, reduced-intensity conditioning; Sir, sirolimus; Tac, tacrolimus; ns,
nonsignificant.
*Randomized trials.
Biol Blood Marrow Transplant 17:93-100, 2011 99Methotrexate for Prevention of Graft-versus-Host Diseaseregimen. We also observed a trend toward better sur-
vival rates with a concomitant reduction inNRM.This
protective effect was manifest despite the normally in-
creased susceptibility to GVHD associated with the
advanced age of patients in the group receiving
MTX. To our knowledge, no previous study has
addressed the effect of MTX in the specific setting of
unrelated RIC-Allo SCT with ATG included in the
conditioning regimen. Finally, more than 20 years
after it was first reported in the pivotal study by the Se-
attle group, one of the optimal prophylaxis regimens
against GVHD in the setting of an RIC regimenmight
very well be the same combination of calcineurin in-
hibitor and short-course treatment with MTX found
to be so effective in the MA setting. This finding
may underline the existence of a major role for MTX
in combination with CsA in the suppression of alloge-
neic T cells as both agents have been found to act on T
cells. Additionally, as MTX also inhibits B cell activity,
our findings may support the recently suggested role
for B cells in the pathophysiology of aGVHD [24,25].
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